ZTS Stock Recent News

Phibro Animal Health Corporation's Zoetis MFA acquisition has revitalized its overall growth. Animal Health is now around 75% of their total sales, and its integration should be finalized by Q4 2025. Post-integration, PAHC believes Zoetis MFAs will normalize to flat growth. But, Vaccines and Nutritional Specialties should continue growing at double digits. PAHC's Phibro Forward initiative is also adding new efficiencies in procurement, commercial, and process improvements.

Zoetis is a global leader in animal health with strong organic growth, robust product innovation, and strategic M&A driving long-term revenue and earnings expansion. The company boasts exceptional dividend safety, a 13-year double-digit dividend growth streak, and a conservative payout ratio, making it ideal for dividend growth investors. Zoetis's current valuation is slightly below historical averages, presenting an attractive entry point with the stock trading near fair value and strong analyst support.

Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8 at 1:05 p.m. ET. Investors and other interested parties can access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world's.

Zoetis remains the global leader in animal health, with 68% of revenue from companion animals. Q2 results showed 8% organic sales growth and 15% adjusted earnings growth. Librela sales in the U.S. declined 16% due to reported side effect concerns.

Right now is not a good time in the healthcare sector. Various companies across the space are well below highs while the broader stock market chugs along at all-time highs.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate principal amount of 4.150% senior notes due 2028 and $1.0 billion aggregate principal amount of 5.000% senior notes due 2035, in an underwritten public offering. Zoetis intends to use the net proceeds to repay the principal of (i) its 4.500% senior notes due 2025 in the aggregate principal amount of $750 million, (ii) its 5.4.

Ah, 10 years ago. It was 2015, and selfie sticks and hoverboards were all over.

Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?

It can be tempting to try to predict market movements so you buy low and sell high, but it's notoriously difficult to execute successfully. Even if you succeed once or twice, replicating that often enough to build a profitable portfolio that stands the test of time is next to impossible.